Estrone and 17β-Estradiol Reverse Breast Cancer Resistance Protein-mediated Multidrug Resistance

Yasuo Imai,1 Satomi Tsukahara,1 Etsuko Ishikawa,1 Takashi Tsuruo2, 3 and Yoshikazu Sugimoto1, 4

1Division of Molecular Biotherapy and 2Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 1-37-1 Kami-Ikebukuro, Toshima-ku, Tokyo 170-8455 and 1Institute of Molecular and Cellular Biosciences, University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-0032

Breast cancer resistance protein (BCRP), an adenosine triphosphate-binding cassette transporter, confers resistance to a series of anticancer reagents, including mitoxantrone, SN-38 and topotecan. In the present study, we found that estrone and 17β-estradiol potentiated the cytotoxicity of mitoxantrone, SN-38 and topotecan in BCRP-transduced K562 cells (K562/BCRP). These estrogens showed only a marginal effect, or none, in parental K562 cells. Estrone and 17β-estradiol increased the cellular accumulation of topotecan in K562/BCRP cells, but not in K562 cells, suggesting that these estrogens inhibit the BCRP-mediated drug efflux and overcome drug resistance.

Key words: BCRP — Estrone — 17β-Estradiol — MDR — Reversal of drug resistance

Multidrug drug resistance (MDR) is a common phenomenon in cancer cells. Cancer cells selected for resistance to a certain chemotherapeutic agent often reveal cross-resistance to structurally unrelated antitumor agents.2, 3 Family members of adenosine triphosphate-binding cassette (ABC) transporters, such as MDR1 gene product P-glycoprotein and multidrug resistance-associated protein (MRP) 1, are involved in multidrug resistance by pumping out a variety of structurally and functionally diverse antitumor drugs from cells.2, 3 Breast cancer resistance protein (BCRP), also called ABCP or MXR, is a newly discovered ABC transporter. It mediates resistance to such chemotherapeutic agents as mitoxantrone, SN-38 (an active metabolite of CPT-11) and topotecan, presumably by pumping these reagents out of the cell to lower the cytotoxic effects.4–8 Overcoming MDR is a major problem in the clinical management of cancer. In order to identify agents which reverse BCRP-mediated drug resistance, we examined the effect of various organic compounds on the toxicity of mitoxantrone, SN-38 and topotecan in BCRP-expressing K562 cells. Among the compounds tested, estrone and 17β-estradiol were found to reverse BCRP-mediated drug resistance.

BCRP retrovirus-producing PA/MycBCRP cells were grown in high-glucose Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum at 37°C with 5% CO2. K562 human leukemic cells were grown in RPMI-1640 medium supplemented with 10% fetal bovine serum at 37°C with 5% CO2. K562 cells were transduced with the retrovirus supernatant for one day and cultured further for 2 days in the same medium without the retrovirus supernatant. Cells were then treated with SN-38 (20 ng/ml) for 5 days to enrich the transduced cells. The expression of BCRP in BCRP-transduced K562 (K562/BCRP) cells was detected with the anti-BCRP polyclonal antibody 3488.9

The effects of chemical compounds on the sensitivity of cells to mitoxantrone, SN-38 and topotecan were evaluated by measuring cell growth inhibition after incubation at 37°C for 5 days in the absence or presence of various concentrations of anticancer drugs in combination with the chemicals examined. Cell numbers were determined with a Coulter counter. IC50 values (drug dose causing 50% inhibition of cell growth) were determined from growth inhibition curves.

The effect of steroidal compounds on cellular accumulation of topotecan was determined by flow cytometry. Cells (5×105) were incubated with 20 µM topotecan for 30 min at 37°C in the absence or presence of modifying agents, washed in ice-cold phosphate-buffered saline, and subjected to fluorescence analysis using a FACS Calibur (Becton-Dickinson, San Jose, CA).

The expression of BCRP in K562/BCRP cells was observed in BCRP-transduced K562/BCRP cells, but not in parental K562 cells. In the presence of reducing agents, BCRP was recognized as a 70-kDa protein by western blot analysis (Fig. 1). K562/BCRP cells showed significantly higher resistances to mitoxantrone, SN-38, and topotecan than K562 cells (Table 1). K562 and K562/BCRP cells showed similar sensitivity to camptothecin, vincristine, and paclitaxel. K562 and K562/BCRP cells expressed...
very small amounts of \textit{MDR1}, \textit{MRP1}, \textit{MRP2}, and \textit{MRP3} mRNAs as determined by reverse transcription-polymerase chain reaction. BCRP transduction did not affect the expression of these transporter mRNAs (data not shown).

The reversal activities of steroids were examined by using fixed doses of steroids (3 and 10 \( \mu M \)) in combination with increasing concentrations of the antitumor agents (Fig. 2). These steroids alone showed only a marginal growth-inhibitory effect, or none, on either K562 or K562/BCRP cells at the doses used in Fig. 2 (Table II). Experimental data for 10 \( \mu M \) 17\( \beta \)-estradiol are not shown because of the excessive growth-inhibitory effect. Estrone enhanced the cytotoxicity of mitoxantrone, SN-38 and topotecan on K562/BCRP cells in a dose-dependent manner, while it did not affect the cytotoxicity of any of these drugs on K562 cells. The reversal activities (the ratios of IC\textsubscript{50} values in the absence or presence of the steroid) of 10 \( \mu M \) estrone were 7.5-fold for mitoxantrone, 3.6-fold for SN-38 and 4.1-fold for topotecan. Similarly, 17\( \beta \)-estradiol enhanced the cytotoxicity of the antitumor agents on K562/BCRP cells, but not K562 cells. Drug resistance was slightly overcome by estriol and pregnenolone in a dose-dependent manner. However, it is not clear whether this reversal was solely attributable to the inhibition of BCRP-mediated drug transport, because estriol and pregnenolone also potentiated the cytotoxicity of these antitumor reagents in parental K562 cells. Progesterone had little effect on the drug sensitivity of K562/BCRP cells.

\begin{table}[h]
\centering
\begin{tabular}{|l|c|c|c|}
\hline
\textbf{Drug} & \textbf{IC\textsubscript{50} (ng/ml)} & \textbf{Degree of resistance} \\
\hline
Mitoxantrone & 0.27 & 3.0 & 11 \\
SN-38 & 0.58 & 12 & 21 \\
Topotecan & 3.3 & 37 & 11 \\
\hline
\end{tabular}
\caption{Drug Resistance of K562/BCRP Cells}
\end{table}

Degree of resistance is the ratio of IC\textsubscript{50} value for K562/BCRP cells divided by that for K562 cells. Data are mean values of triplicate determinations. Standard deviations are less than 10\% of the mean values.

Fig. 1. Expression of BCRP in K562/BCRP cells. Western blot analysis was performed under reducing conditions, revealing BCRP as a 70-kDa band (arrow).

Fig. 2. Reversal effect of steroids on antitumor drug resistance. K562 ( ) and K562/BCRP ( ) cells were cultured for 5 days in the absence ( ) or presence of 3 \( \mu M \) ( ), 10 \( \mu M \) ( ) steroid with increasing doses of antitumor drugs: estrone (A), 17\( \beta \)-estradiol (B), estriol (C), pregnenolone (D), progesterone (E). Antitumor agents are mitoxantrone (N-1), SN-38 (N-2), and topotecan (N-3) (N: A–E). (Each point is an average of triplicate determinations). Cell numbers were counted with a Coulter counter. For 17\( \beta \)-estradiol, data for 10 \( \mu M \) are omitted because of high cytotoxicity.
Interestingly, the cytotoxicity of mitoxantrone to parental K562 cells was enhanced in the presence of progesterone, but that of the other antitumor reagents was not. The reason for this result is unclear, but progesterone and mitoxantrone might have synergistic effects on K562 cells.

Some steroids and their metabolites are substrates of P-glycoprotein and MRP1. P-Glycoprotein excretes hydrocortisone and aldosterone. Glucuronides such as 17β-estradiol-17β-D-glucuronide are substrates of MRP1. However, hydrocortisone, aldosterone and 17β-estradiol-17β-D-glucuronide did not overcome drug resistance of K562/BCRP cells. K562 and K562/BCRP cells showed similar and marginal expression of MDR1 and MRP1 mRNAs by reverse transcription-polymerase chain reaction. These results suggest that estrone and 17β-estradiol interact specifically with BCRP and overcome drug resistance of K562/BCRP cells.

In order to determine whether this reversal might be associated with increased drug transport, the cellular accumulation of topotecan was evaluated in the absence or presence of steroid hormones by flow cytometric analysis. Intracellular accumulation of topotecan increased in the presence of estrone in a dose-dependent manner in K562/BCRP cells, whereas the levels were not altered in K562 cells (Fig. 3). In addition, increased cellular accumulation of topotecan was also observed in the presence of 17β-estradiol and estriol. Pregnenolone and progesterone showed marginal effects on topotecan uptake. These results indicate that estrone and 17β-estradiol reversed topotecan resistance by increasing the cellular levels of topotecan in BCRP-expressing cells. The other steroids, especially estriol, induced little reversal of the drug resistance as detected in the growth inhibition assay, although estriol strongly enhanced topotecan uptake in K562/BCRP cells. This discrepancy could be attributable to the differences in the concentrations of the steroids tested, and resistance to these drugs might have been overcome in the growth inhibition assay if higher concentrations of steroids had been used. Intracellular topotecan accumulation in

Table II. Steroid Sensitivity of K562/BCRP Cells

| Steroid     | IC50 (µM) K562 | IC50 (µM) K562/BCRP | Degree of resistance |
|-------------|----------------|---------------------|---------------------|
| Estrone     | >100           | >100                | ND                  |
| 17β-Estradiol | 5.9          | 4.8                 | 0.8                 |
| Estriol     | 19.4           | 16.7                | 0.86                |
| Pregnenolone | 32.3          | 21.9                | 0.68                |
| Progesterone | 10.6          | 9.2                 | 0.87                |

Degree of resistance is the ratio of IC50 value for K562/BCRP cells divided by that for K562 cells. Data are mean values of triplicate determinations. Standard deviations are less than 10% of the mean values. ND: not determined.

Fig. 3. Effect of steroids on the intracellular uptake of topotecan in K562 and K562/BCRP cells. Cells were incubated with or without 20 µM topotecan in the presence or absence of the steroid: (—), with topotecan; (----), without topotecan. Uptake of topotecan was measured by FACS. In K562/BCRP cells, a fluorescence peak shift to the right indicates cellular uptake of topotecan in the presence of steroids, while no shift occurred in the absence of steroids. In contrast, fluorescence peak shifts to the right were observed in K562 cells, irrespective of the status of steroids.
K562/BCRP cells slightly increased in the presence of pregnenolone, so that the enhanced cytotoxicity of antitu-
mer drugs observed in the growth inhibition assay might be, in part, explained by the inhibition of BCRP-mediated
drug efflux.

Therefore, we infer that steroid hormones, especially estrone and 17β-estradiol, may be physiological substrates
for BCRP and act to competitively inhibit drug transport. Among normal tissues, the highest levels of BCRP
expression are recognized in the placenta, and BCRP is presumed to play a role in protecting the fetus against toxic
compounds. In addition, BCRP expression has been observed in the syncytiotrophoblast of the placenta that
produces the steroid hormones evaluated in this study.12

Although K562 and K562/BCRP cells showed similar
sensitivity to the steroids, as shown in Table II, our pre-
liminary experiments suggest that BCRP transports estrone
and 17β-estradiol, but not progesterone, in the basal to
apical direction in BCRP-transduced LLC-PK1 cells (manu-
script in preparation). A detailed investigation is currently
under way to confirm the hypothesis that these steroids
are physiological substrates for BCRP.10,13

REFERENCES

1) Gottesman, M. M., Hrycyna, C. A., Schoenlein, P. V.,
Germamm, U. A. and Pastan, I. Genetic analysis of the
multidrug transporter. Annu. Rev. Genet., 29, 607–649
(1995).

2) Chen, C. J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I.,
Gottesman, M. M. and Roninson, I. B. Internal duplication and
homology with bacterial transport proteins in the
mdr1 (P-glycoprotein) gene from multidrug-resistant human cells.
Cell, 47, 381–389 (1986).

3) Ueda, K., Clark, D. P., Chen, C. J., Roninson, I. B.,
Gottesman, M. M. and Pastan, I. The human multidrug
resistance (mdr1) gene. cDNA cloning and transcription ini-
tiation. J. Biol. Chem., 262, 505–508 (1987).

4) Miyake, K., Mickley, L., Litman, T., Zhan, Z., Robey, R.,
Cristensen, B., Brangi, M., Greenberger, L., Dean, M.,
Foyo, T. and Bates, S. E. Molecular cloning of cDNA
which is highly expressed in mitoxantrone-resistant
cells: demonstration of homology to ABC transport genes.
Cancer Res., 59, 8–13 (1999).

5) Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T.,
Gao, Y., Rishi, A. K. and Ross, D. D. A multidrug resistance
transporter from human MCF-7 breast cancer cells.
Proc. Natl. Acad. Sci. USA, 95, 15665–15670 (1998).

6) Allikmets, R., Schriml, L., Hutchinson, A., Romano-Spica,
V. and Dean, M. A human placenta-specific ATP-binding
cassette gene (ABCP) on chromosome 4q22 that is involved in
multidrug resistance. Cancer Res., 58, 5337–5339
(1998).

7) Maliepaard, M., van Gastelen, M. A., de Jong, L. A., Plijm,
D., van Waardenburg, R. C., Ruevekamp-Helmers, M. C.,
BCRP is overexpressed in some cancer cell lines other
than those of the genital organs, such as lung A549 and
colon KM12 cells, and may underlie the natural resistance
to antitumor agents.14) GF120918 and fumitremorgin C
have been found to reverse BCRP-mediated drug resis-
tance.15,16) Estrone and 17β-estradiol are the first endoge-
nous compounds shown to exert strong reversal activity.
Steroid analogs without estrogenic or anti-estrogenic
activity might be used to overcome BCRP-mediated drug
resistance without significant side effects.

In summary, estrogens were found to restore drug sensi-
tivity in K562/BCRP cells by increasing the cellular accu-
mulation of anticancer drugs. These findings should assist
practical therapy and the design of more effective and
safer reagents to circumvent drug resistance, as well as
having implications for the physiological role of BCRP.

This work was supported in part by grants from Ministry of
Education, Culture, Sports, Science and Technology, and Minis-
try of Health, Labour and Welfare, Japan.

(Received November 13, 2001/Revised January 7, 2002/
Accepted January 22, 2002)
Estrogens Reverse BCRP-mediated Drug Resistance

R. J. and Horwitz, S. B. Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus. *J. Biol. Chem.*, **264**, 782–788 (1989).

14) Robey, R. W., Honjo, Y., van de Laar, A., Miyake, K., Regis, J. T., Litman, T. and Bates, S. E. A functional assay for detection of the mitoxantrone resistance protein, MXR (ABCG2). *Biochim. Biophys. Acta*, **1512**, 171–182 (2001).

15) De Bruin, M., Miyake, K., Litman, T., Robey, R. and Bates, S. E. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. *Cancer Lett.*, **146**, 117–126 (1999).

16) Rabindran, S. K., Ross, D. D., Doyle, A., Yang, W. and Greenberger, L. M. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. *Cancer Res.*, **60**, 47–50 (2000).